BIOTRONIK: Global Expansion of a $1.5B Cardiac Pacemaker Leader

In 1967, BIOTRONIK, which originated in West Berlin, crossed the Berlin Wall during a customer visit and became the pacemaker supplier for a renowned hospital in central East Berlin. This trip to East Germany marked the first step in BIOTRONIK’s international expansion journey.

BIOTRONIK, which embarked on its global expansion just three years after its founding, has since become a global leader in cardiovascular medical devices and clinical solutions, with its products and services available in more than 100 countries and regions worldwide.

Amid the prevailing trend of Chinese innovators collectively expanding overseas, identifying an internationalization pathway suited to their own development has become the top priority for medical device enterprises. Against this backdrop, VCBeat analyzes BIOTRONIK’s nearly 60 years of global expansion practices to provide reference for relevant companies.

First, let us review the product development history of BIOTRONIK. In the 1960s, global pacemaker technology was still in its early stages, plagued by issues such as battery life lasting less than a year and difficulties in handling electrode leads. German scientist Max Schaldach and electronic engineer Otto Franke decided to develop Germany’s first pacemaker, aiming for performance that surpassed existing models—not only with a longer service life but also with greater practical utility for clinical practice.

With the assistance of the Heinrich Hertz Institute, the duo obtained the most advanced materials available at the time. Through their relentless day-and-night efforts, Germany’s first cardiac pacemaker was developed in 1963. The PIP-3 model consumed less energy and weighed 15 grams (approximately 15%) less than competing products. By the end of that year, the device was successfully implanted in a human patient for the first time and functioned effectively.

To this day, BIOTRONIK, which started with pacemakers, has not only grown into one of the global leaders in the pacemaker market but also belongs to the first tier in the fields of cardiovascular intervention and electrophysiology. It has formed four major business lines: cardiac rhythm management, electrophysiology, vascular intervention, and neuromodulation.

BIOTRONIK places significant emphasis on investment in research and development. In the first half of 2024 alone, BIOTRONIK’s product advancements were particularly remarkable.

In the field of cardiac rhythm management (CRM), BIOTRONIK focuses on developing innovative therapies and technologies for heart disease, with a product portfolio that includes pacemakers, implantable defibrillators, leads, and remote monitoring solutions.

In February 2024, BIOTRONIK announced the successful implantation of 100,000 single-chamber implantable cardioverter-defibrillators (ICDs) equipped with DX technology. Since its launch in 2009, DX ICDs have been used by clinicians in more than 80 countries across all continents worldwide.

More than 20 clinical studies conducted by BIOTRONIK over the past few decades have confirmed the safety and efficacy of DX technology. Recent results from the MATRIX study demonstrate that, under real-world conditions, DX technology combined with home monitoring enables reliable, guideline-recommended remote monitoring of subclinical atrial fibrillation.

In Europe and the United States, remote follow-up monitoring has been widely adopted and proven to enable early detection of clinical events, particularly asymptomatic ones, thereby reducing emergency department visits and hospital length of stay while improving survival rates among patients with cardiac implantable electronic devices (CIEDs). As early as 2000, BIOTRONIK’s Home Monitoring system was utilized in technical feasibility studies and received FDA clearance the following year. BIOTRONIK became the first company to introduce remote monitoring devices in the United States, earning its place in the “FDA Hall of Fame” that year. In 2023, BIOTRONIK optimized its Home Monitoring technology and launched a new neuromodulation technology that allows for faster and more precise adjustments, ultimately benefiting patients.

In April 2024, BIOTRONIK’s latest implantable cardiac monitor, the ICM-Biomonitor IV, received CE marking, becoming the first such implant approved in Europe. The device combines BIOTRONIK’s SmartECG technology with artificial intelligence (AI), reducing false-positive monitoring alerts by up to 86% and achieving a diagnostic accuracy of up to 98%.

What sets this device apart is its ability to distinguish between premature ventricular contractions (PVCs) and atrial contractions—a first for implantable cardiac monitors (ICMs) on the market. This not only enhances the efficiency of arrhythmia monitoring but also provides healthcare professionals with a more accurate tool for risk stratification and diagnosis, thereby improving the diagnostic and therapeutic management of patients with cardiac diseases.

In the field of electrophysiology, BIOTRONIK provides patients with arrhythmias with 3D imaging, ablation, diagnostic, and transseptal solutions for diagnosis or treatment.

In 2003, to provide effective and safe treatment for patients with atrial fibrillation, BIOTRONIK launched the AlCath Flux eXTRA Gold ablation catheter. Featuring a pure gold tip, it offers four times the thermal conductivity of conventional catheters. Its three-dimensional structure ensures optimal heat distribution and superior heat dissipation, making it one of the most effective and safest therapies for patients with atrial fibrillation. At an event commemorating the 20th anniversary of the Gold TIP ablation catheter’s market launch, BIOTRONIK stated that the Gold TIP remains a key component of its electrophysiology technology. For instance, its integration with contact-force ablation and unique non-contact imaging and mapping systems continues to influence electrophysiological ablation procedures.

In the field of neuromodulation, BIOTRONIK creates personalized and highly effective pain management solutions, encompassing innovations such as spinal cord stimulation, remote management, and proactive care.

In April 2023, BIOTRONIK’s Prospera Spinal Cord Stimulation (SCS) System received FDA approval. This system integrates daily remote monitoring and remote programming capabilities, enabling tailored SCS therapy for patients with chronic refractory pain and facilitating more rapid optimization of treatment regimens when adjustments are needed. This also marks BIOTRONIK’s first significant market approval in a new therapeutic area.

In 1995, BIOTRONIK established a cardiovascular business division, offering cutting-edge products such as coronary drug-eluting stents, balloons, drug-coated balloons, and bioresorbable scaffolds.

Although it entered the market relatively late, BIOTRONIK quickly overtook competitors by leveraging its technological expertise in the cardiovascular field. Today, BIOTRONIK offers a strong portfolio of products for bradycardia, tachycardia, cardiac resynchronization therapy, external devices, coronary vascular access, and peripheral vascular access.

In 2011, BIOTRONIK introduced Orsiro, the world’s first hybrid drug-eluting stent with a bioresorbable coating, ushering in a new era in the treatment of coronary artery disease. This stent delivers high precision even in complex vascular anatomies. The inert proBIO coating envelops the stent, minimizing interactions with surrounding human tissue. The BIOlute active coating combines the drug with a distinctive bioresorbable polymer matrix to ensure controlled drug release.

In 2021, BIOTRONIK launched the “world’s thinnest absorbable percutaneous coronary intervention stent,” namely the Orsiro Mission bioresorbable polymer drug-eluting stent system (BP-DES). In June 2023, the Oscar multifunctional peripheral catheter was launched in the European market.

In January 2024, BIOTRONIK announced the approval and market launch in China of its first paclitaxel-coated balloon, Passeo-18 Lux. Meanwhile, news that “BIOTRONIK is considering selling its coronary stent and balloon catheter business” has attracted significant attention. According to Cybersino Medical Devices, BIOTRONIK plans to divest this business to alleviate its current debt burden of approximately €600 million and to focus on its core operations.

According to foreign media reports, BIOTRONIK’s total revenue exceeded €1.5 billion (approximately RMB 11.77 billion), achieving significant growth in 2023. This divestiture aims to streamline operations, focus on core businesses, and ensure financial stability.

Focusing energy on core business has also been a key reason for BIOTRONIK’s growth and strength. In its early days, BIOTRONIK devoted itself to product development; it was only after three years that the company established representative offices and began visiting potential clients one by one to acquire customers.

On one occasion, Schaldach, who was responsible for client communications, crossed the Berlin Wall with plans to visit the renowned Charité Hospital in central East Berlin. Despite facing numerous challenges, including cumbersome exit procedures, multiple hospitals in East Germany, including Charité Hospital, soon became clients of BIOTRONIK.

Observing BIOTRONIK’s global expansion trajectory, we find that it comprises three stages: with East Germany as the initial overseas market, it gradually covered the European market; in the 1980s, the expansion into the American market commenced; and in the 1990s, it embarked on its development journey in the Asia-Pacific region, rapidly gaining prominence.

In 1973, ten years after the first implantation of its pacemaker in humans, BIOTRONIK established its first sales team. Within just three years, it entered the Austrian and French markets and opened its first international branch. In 1979, the company further expanded its presence to the United Kingdom and Ireland.

In the global medical device market, Europe is a market that cannot be overlooked. Economically, Europe is the most developed continent in the world, with the European Union’s total GDP reaching $16.65 trillion in 2022. Meanwhile, countries such as Germany, France, and Belgium allocate a relatively high proportion of their spending to healthcare; for instance, Germany’s healthcare expenditure reached €440.6 billion in 2020, accounting for 13.1% of its GDP. Benefiting from its advanced economy and ample healthcare budgets, Europe ranks among the top regions globally in the medical device sector, standing as the second-largest medical device market after the United States.

The cardiac rhythm management industry features exceptionally high barriers to entry in terms of technology, market concentration, regulation, and services. Leveraging its local advantages, BIOTRONIK rapidly established strengths in technological products, brand reputation, physician trust, and service capabilities. In addition to its German headquarters, BIOTRONIK established a factory in Zurich, Switzerland, in 1999 to produce balloon catheters and stents for the treatment of cardiovascular diseases. Soon thereafter, BIOTRONIK became a leading player in the European pacemaker market.

While expanding into the European market, BIOTRONIK also extended its reach to the Americas. In 1979, BIOTRONIK established a new manufacturing plant in Oregon, USA, marking the beginning of its large-scale expansion in the 1980s. By 1986, monthly sales of BIOTRONIK pacemakers in the United States reached 120 units. While this figure may seem modest by today’s standards, it instilled significant confidence in BIOTRONIK’s U.S. team at the time.

In the 1980s, there were few companies in the American cardiac pacemaker market. Apart from Medtronic, St. Jude Medical (which acquired Pacesetter in 1994) and Boston Scientific (which acquired Guidant in 2006) had not yet formally entered the pacemaker market. This situation provided BIOTRONIK with an opportunity to expand its market presence to some extent.

In 2023, the market size of cardiovascular devices in North America reached USD 32.07 billion. The presence of industry giants such as Medtronic, Boston Scientific, and Abbott, coupled with the rising prevalence of heart disease in the United States and Canada, are key factors driving and facilitating market expansion during the forecast period. Consequently, North America remains a critical strategic market that global pacemaker manufacturers are unwilling to relinquish.

In 1989, BIOTRONIK expanded its focus further south by establishing a Brazilian office in São Paulo, where operations have continued to this day. Brazil also serves as the coordinating headquarters for all of BIOTRONIK’s businesses in Latin America.

It is worth noting that the Brazilian Health Regulatory Agency (ANVISA) has announced that, starting from June 2024, Brazil will accept medical device registration approvals from the United States, Canada, Japan, and Australia as references for Class III and Class IV medical devices and in vitro diagnostics (IVD), so as to accelerate the registration and approval process for medical devices in Brazil. This move will also bring new opportunities and challenges to the Brazilian medical device market.

In 1999, BIOTRONIK established an office in Australia, marking the beginning of its expansion journey in the Asia-Pacific region. Since entering the 21st century, BIOTRONIK has rapidly expanded its investments in the Asia-Pacific region and opened offices in countries and regions such as China, India, and South Korea.

BIOTRONIK has established offices in more than 100 countries and regions worldwide, butTo ensure product reliability and the manufacturing supply chain,Production facilities have been established exclusively in four countries: Germany, Switzerland, the United States, and Singapore. These locations were selected due to their robust regulatory frameworks, extensive accumulation of medical research and clinical resources, as well as their strong manufacturing capabilities and R&D prowess.

Take Singapore as an example. BIOTRONIK established its Asia-Pacific headquarters in 2012 and built its first production facility in the region in 2016. At the end of 2023, BIOTRONIK also announced the opening of its new Asia-Pacific Manufacturing and R&D Center in Singapore. Spanning 20,000 square meters, this facility will serve as the company’s central hub for the Asia-Pacific region, employing hundreds of staff engaged in manufacturing, quality assurance, research and development, sales, and marketing.

Singapore is Asia’s leading global hub for biomedical sciences. All of the world’s top 30 multinational medical technology companies have established regional headquarters, R&D centers, or manufacturing facilities here. Coupled with the vigorous growth of more than 400 local startups and small- and medium-sized medtech enterprises, Singapore has become one of the core global regions for medical technology R&D and manufacturing. For Chinese medtech companies, Singapore’s business environment and R&D ecosystem offer significant opportunities for market growth. Leading domestic healthcare enterprises such as Sinopharm Group, Kexing Biologics, GenScript, and WuXi Biologics have successively set up manufacturing facilities in Singapore.

BIOTRONIK’s Story in China Began in 1992BIOTRONIK GmbH & Co. KG’s Beijing Representative Office was originally responsible for its business operations in China. In 2007, this entity was officially upgraded to BIOTRONIK (Beijing) Medical Device Limited.

BIOTRONIK has launched its full product portfolio in the Chinese market, including pacemakers, cardiac resynchronization therapy (CRT) devices, and implantable cardioverter-defibrillators (ICDs). In January 2024, Passeo-18 Lux, its first peripheral paclitaxel-coated drug-eluting balloon, received regulatory approval for market entry in China. According to incomplete statistics, BIOTRONIK has obtained approval for more than 60 medical devices in China.

China’s cardiac rhythm management market is dominated almost entirely by Medtronic, Abbott, Boston Scientific, andBIOTRONIKMonopoly. According to data from the Medical Device Data Cloud, BIOTRONIK ranked third in the 2023 annual bidding results for pacemaker brands, trailing only Medtronic and Lifetech Scientific, with its total winning bid amount accounting for 13.6% of the market. Currently, under the monopoly of foreign enterprises, only a few domestic companies—such as MicroPort CRM, Lifetech Scientific, Lepu Medical, Wushuang Medical, and Vivasure—have established a presence in China’s cardiac rhythm management market. However, with the implementation of centralized procurement policies, Chinese companies are trading price for market share. Coupled with continuous breakthroughs in technology and products by domestic firms, Chinese cardiac rhythm management companies are poised to seize opportunities for accelerated development.